 CAMBRIDGE, Mass., Aug. 25, 2022 GLOBE NEWSWIRE -- Immuneering Corporation Nasdaq: IMRX, a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today announced that management will participate in two September investor conferences to share commentary around the Companys pipeline, platform, and business strategy. Presenting will be Ben Zeskind, Ph.D., Co-Founder, and Chief Executive Officer and Brett Hall, Ph.D., Chief Scientific Officer. 